Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Q4 FY25 Earnings Presentation
20 slides from Caplin Point Laboratories's earnings presentation, May 2025
Slide 1: Earnings Presentation Q4 FY25
EARNINGS PRESENTATION Q4 FY25 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* May 2025 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Q4 FY25 Income Statement
Q4 FY25 Income Statement Revenue from Operations Gross Profit EBITDA 11% 17% 19% YoY YoY 502 YoY 194 194 493 298 301 163 453 257 Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 EBIT PAT Earnings Per Share 21% 20% YoY YoY 177 177 145 18.75 140 18.28 146 121 16.01 Q4 FY24 Q3 FY
Slide 4: Q4 FY25 Profit Margins
Q4 FY25 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 60.4% 36.9% 36.7% 60.0% 56.6% 34.5% Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 EBIT Margins (%) PAT Margins (%) 33.8% 27.5% 26.7% 33.5% 25.8% 31.1% Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 4
Slide 5: FY25 Income Statement
FY25 Income Statement Revenue from Operations Gross Profit EBITDA 14% 20% 20% YoY YoY YoY 1,937 743 1,167 618 970 1,694 FY24 FY25 FY24 FY25 FY24 FY25 EBIT PAT Profit Margins 20% 17% YoY YoY 57.3% 60.2% 677 541 35.1% 36.5% 32.1% 33.3% 565 461 26.2% 26.6% FY24 FY25 FY24 FY25 FY24 FY25 Gross Profit EBI
Slide 6: FY25 Cash and Cash Equivalents and other Key Metrics
FY25 Cash and Cash Equivalents and other Key Metrics Cash and Cash Equivalents Capital Investment Lifecycle 1,180 Cash Flow from Operation: ₹ 432 Cr 916 194 192 772 694 146 470 91 77 73 284 65 223 47 49 101 126 26 26 27 46 68 8 Free Cashflow: ₹ 240 FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 FY 20 FY 21 FY
Slide 7: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Mr. Vivek Partheeban Point Laboratories said: • Managing Director • Chief Operating Officer We’re delighted to close out another year with excellent
Slide 8: Q4 FY25 Highlights (Emerging Markets)
Q4 FY25 Highlights (Emerging Markets) 01 02 03 04 05 Company’s wide portfolio mix of Mexico Update – Company has Caplin continues robust growth in Company renews focused shift filed 30+ products, with 13 Revenue and Profitability from Generics and Branded Generics to asset light Outsourcing Company
Slide 9: Q4 FY25 Highlights (US and Regulated markets)
Q4 FY25 Highlights (US and Regulated markets) 01 02 03 04 CSL receives 8 new ANDA approvals in Company launches its first RTU Bag, Caplin Steriles Limited (CSL) closes the Company expects 10-12 ANDA FY-25 with another 2 ANDAs acquired first Opthalmic Emulsion and first year with strong Revenue and E
Slide 10: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple Incorporates Caplin projects equaling INR 600 Work on Regulated Steriles USA Inc for Listed on Stock Started outsourcing from Started first commercial Cr. CRO wing Amaris Markets Injectable unit launching own label in US Exchange China
Slide 11: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved). R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue 2 Continuous capex investment of over INR 887 Cr over last 8 years towards 89 85 enhanced manufacturing and R&D capabilities, from internal acc
Slide 12: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY25 Operating Revenue (Emerging Markets) (Emerging Markets) 35% 18% 6% 75% 25% 20% 76% 45% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 13: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 13
Slide 14: Caplin Point Structure
Caplin Point Structure Caplin Point Laboratories Caplin Point Far East Ltd Caplin Steriles Ltd (BSE: 524742| NSE: CAPLIPOINT) (India) Subsidiaries Manufacturing Units: Manufacturing Units: • CP I: Puducherry • Nuevos Eticos Neo Ethicals S.A. • CP IV: Gummidipoondi • CP X: Vishakhapatnam Guatemala •
Slide 15: Manufacturing and R&D Platform
Manufacturing and R&D Platform Location of Plants and Facilities Tamil Nadu, India 1. SIDCO, Kakkalur, Near Chennai 1 2 2. Gummidipoondi, Chennai (CP4) 43 3. Thervoy SIPCOT, Chennai 5 4. Corporate Office, Chennai 5. Suthukeny, Puducherry (CP1) 6. APIIC, Visakhapatnam CP I CP III Puducherry Chengalpa
Slide 16: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline Lyophilized CP1, Suthukeny, Caplin Plant I Injectables and Dual Existing Markets Nearing Completion Q1 FY26 Puducherry Chamber Syringes. Caplin Steriles CP4, Line 5 – Completed. Injectable Vials and Gummidi
Slide 17: Caplin Point's Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 18: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Mr. R. Vijayaraghavan Chairman Managing Director Independent Director Independent Director Independent Director Independent Director 30+ Years of 35+ Years exp
Slide 19: P&L for the Q4 FY25 – Consolidated
P&L for the Q4 FY25 – Consolidated Value (₹ in Cr) Q4 FY25 Q4 FY24 YoY (%) Q3 FY25 QoQ (%) FY25 FY24 YoY (%) Revenue from Operation 502.45 453.22 10.9% 492.96 1.9% 1,937.47 1,694.10 14.4% Other Income 25.74 17.29 48.9% 31.36 (17.9)% 96.43 66.94 44.0% Total Revenue 528.19 470.51 12.3% 524.32 0.7% 2,0
Slide 20: Investor Relations at Caplin
INVESTOR RELATIONS AT CAPLIN Mr G Venkatram [email protected] CHURCHGATE PARTNERS Simran Malhotra / Rajiv Pandya [email protected] 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited
Caplin Point Laboratories — Q4 FY25 Earnings Presentation on 6ix